[go: up one dir, main page]

AR035026A1 - Uso de pentosan polisulfato en el tratamiento de ciertas condiciones de la prostata - Google Patents

Uso de pentosan polisulfato en el tratamiento de ciertas condiciones de la prostata

Info

Publication number
AR035026A1
AR035026A1 ARP010100243A ARP010100243A AR035026A1 AR 035026 A1 AR035026 A1 AR 035026A1 AR P010100243 A ARP010100243 A AR P010100243A AR P010100243 A ARP010100243 A AR P010100243A AR 035026 A1 AR035026 A1 AR 035026A1
Authority
AR
Argentina
Prior art keywords
prostate
treatment
pentosan
polisulfate
certain conditions
Prior art date
Application number
ARP010100243A
Other languages
English (en)
Inventor
Gary E Striker
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of AR035026A1 publication Critical patent/AR035026A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un método de tratamiento de una condición de la próstata que comprende administrar a un mamífero que posee una condición de la próstata seleccionada del grupo integrado por hiperplasia prostática benigna, prostatitis crónica, prostadinia, y una condición irritativa de la vejiga, que no sea cistitis intersticial, una cantidad efectiva para el tratamiento de pentosan polisulfato o una sal farmacéuticamente aceptable del mismo.
ARP010100243A 2000-01-19 2001-01-19 Uso de pentosan polisulfato en el tratamiento de ciertas condiciones de la prostata AR035026A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17708300P 2000-01-19 2000-01-19

Publications (1)

Publication Number Publication Date
AR035026A1 true AR035026A1 (es) 2004-04-14

Family

ID=22647123

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100243A AR035026A1 (es) 2000-01-19 2001-01-19 Uso de pentosan polisulfato en el tratamiento de ciertas condiciones de la prostata

Country Status (4)

Country Link
US (2) US20020010140A1 (es)
AR (1) AR035026A1 (es)
AU (1) AU2001230994A1 (es)
WO (1) WO2001052867A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7502229B2 (en) * 2004-10-15 2009-03-10 Alcatel Lucent Heat dissipation system for multiple integrated circuits mounted on a printed circuit board
NZ571537A (en) 2006-04-03 2012-06-29 Nutramax Lab Inc Stabilized pentosan polysulfate (PPS) formulations and methods of analayzing them
AU2008100730B4 (en) * 2008-07-04 2008-10-02 Parnell Technologies Pty Ltd Sulfated polysaccharide compound for clinical use and the preparation thereof
WO2011088418A2 (en) * 2010-01-15 2011-07-21 Mount Sinai School Of Medicine Inhibition of tnf-alpha induced activation of nfkb by pentosan polysulfate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US5643892A (en) * 1995-06-07 1997-07-01 Baker Norton Pharmaceuticals, Inc. Method of treating chronic progressive vascular diseases
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
UA65587C2 (en) * 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus

Also Published As

Publication number Publication date
WO2001052867A1 (en) 2001-07-26
US20020010140A1 (en) 2002-01-24
US6828309B2 (en) 2004-12-07
AU2001230994A1 (en) 2001-07-31
WO2001052867A9 (en) 2002-10-10
US20030040491A1 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
CO2022013777A2 (es) Uso de agentes para el tratamiento de condiciones respiratorias
NO20054988D0 (no) Preparater og metoder for behandling av cancer
AR116859A2 (es) Métodos para tratar la esclerosis múltiple progresiva
DK1071417T3 (da) Anvendelse af cannabidiol som anti-inflammatorisk middel
AR023400A1 (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
AR083395A1 (es) Derivado peptidico nmu (neuromedina u) con elevado efecto anorectico
AR028939A1 (es) Metodo para tratar un desorden pancreatico con una neurotoxina
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
WO2007041398A3 (en) Treatment of cancer with specific rxr agonists
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
AR057295A1 (es) Combinaciones y procedimientos para usar un compuestos de indolinona
EA200101089A1 (ru) Новый способ лечения
WO2025049814A3 (en) Ribonucleotide reductase (rnr) compositions and methods of use
Donnellan et al. Prevention of post‐ERCP pancreatitis
BG106461A (en) Methods and use of rapid onset of reactive serotonin inhibitors for treating sexual dysfunction
AR062658A1 (es) Terapias de combinacion para artritis reumatoide
AR019699A1 (es) Composicion farmaceutica para el tratamiento de disfuncion de la evacuacion y uso de la misma para la preparacion de un agente terapeutico
ES2216630T3 (es) Metodos de tratar la hipertension dependiente de la sal.
ATE359804T1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1- inhibitoren zur behandlung von nierenkrankheiten
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
CO5160295A1 (es) Nuevas combinaciones farmaceuticas para inhibidores de la nos cionalmente un ssri
AR035026A1 (es) Uso de pentosan polisulfato en el tratamiento de ciertas condiciones de la prostata
PT1214061E (pt) Nova utilizacao de docetaxel para o tratamento do carcinoma hepatocelular
ZA202103914B (en) Cxcr7 inhibitors for the treatment of cancer
EP4545072A3 (en) Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia

Legal Events

Date Code Title Description
FB Suspension of granting procedure